866-997-4948(US-Canada Toll Free)

Rectal Cancer - Pipeline Review, H1 2016

Published By :

Global Markets Direct

Published Date : Mar 2016

Category :

Cancer

No. of Pages : 112 Pages

Rectal Cancer - Pipeline Review, H1 2016

Summary

Global Markets Directs, Rectal Cancer - Pipeline Review, H1 2016, provides an overview of the Rectal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Rectal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rectal Cancer and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Rectal Cancer
- The report reviews pipeline therapeutics for Rectal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Rectal Cancer therapeutics and enlists all their major and minor projects
- The report assesses Rectal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Rectal Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Rectal Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Rectal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Rectal Cancer Overview 6
Therapeutics Development 7
Pipeline Products for Rectal Cancer - Overview 7
Rectal Cancer - Therapeutics under Development by Companies 8
Rectal Cancer - Pipeline Products Glance 9
Clinical Stage Products 9
Early Stage Products 10
Rectal Cancer - Products under Development by Companies 11
Rectal Cancer - Companies Involved in Therapeutics Development 12
AbbVie Inc. 12
Advaxis, Inc. 13
Cerulean Pharma, Inc. 14
Hanwha Chemical Corporation 15
Karyopharm Therapeutics, Inc. 16
Regeneron Pharmaceuticals, Inc. 17
Synta Pharmaceuticals Corp. 18
Taiwan Liposome Company, Ltd. 19
Rectal Cancer - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
axalimogene filolisbac - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
CB-24 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
CRLX-101 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
ganetespib - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
HD-204 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
nimotuzumab - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
selinexor - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
TLC-388 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
veliparib - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
ziv-aflibercept (recombinant) - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Rectal Cancer - Recent Pipeline Updates 64
Rectal Cancer - Dormant Projects 108
Rectal Cancer - Product Development Milestones 109
Featured News & Press Releases 109
Apr 23, 2014: Abbvie To Present Data On Veliparib At The 2014 American Society Of Clinical Oncology Annual Meeting 109
Nov 10, 2011: Synta Announces Results Show Ganetespib Sensitizes Rectal Cancer Cells To Chemoradiotherapy 109
Appendix 111
Methodology 111
Coverage 111
Secondary Research 111
Primary Research 111
Expert Panel Validation 111
Contact Us 111
Disclaimer 112

List of Tables
Number of Products under Development for Rectal Cancer, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Clinical Stage Development, H1 2016 9
Comparative Analysis by Early Stage Development, H1 2016 10
Products under Development by Companies, H1 2016 11
Rectal Cancer - Pipeline by AbbVie Inc., H1 2016 12
Rectal Cancer - Pipeline by Advaxis, Inc., H1 2016 13
Rectal Cancer - Pipeline by Cerulean Pharma, Inc., H1 2016 14
Rectal Cancer - Pipeline by Hanwha Chemical Corporation, H1 2016 15
Rectal Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 16
Rectal Cancer - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 17
Rectal Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2016 18
Rectal Cancer - Pipeline by Taiwan Liposome Company, Ltd., H1 2016 19
Assessment by Monotherapy Products, H1 2016 20
Number of Products by Stage and Target, H1 2016 22
Number of Products by Stage and Mechanism of Action, H1 2016 24
Number of Products by Stage and Route of Administration, H1 2016 26
Number of Products by Stage and Molecule Type, H1 2016 28
Rectal Cancer Therapeutics - Recent Pipeline Updates, H1 2016 64
Rectal Cancer - Dormant Projects, H1 2016 108

List of Figures
Number of Products under Development for Rectal Cancer, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Clinical Stage Development, H1 2016 9
Assessment by Monotherapy Products, H1 2016 20
Number of Products by Top 10 Targets, H1 2016 21
Number of Products by Stage and Top 10 Targets, H1 2016 21
Number of Products by Top 10 Mechanism of Actions, H1 2016 23
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 23
Number of Products by Routes of Administration, H1 2016 25
Number of Products by Stage and Routes of Administration, H1 2016 25
Number of Products by Molecule Types, H1 2016 27
Number of Products by Stage and Molecule Types, H1 2016 27

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *